Interestingly, Intas is currently the sole contender left in fray for Mallinckrodt's generics drug business in the US, a potential $1.5-billion transaction that would give the drugmaker access to the attractive therapeutic segment of controlled substances, or opioids, that have steep entry barriers and high ...
Read more: Indian pharma majors weigh bids for Sanofi's $2 billion European generics business